Celularity

OverviewSuggest Edit

Celularity is a biotechnology company developing allogeneic cells and tissues derived from the postpartum placenta. The cells are used to create transformative therapeutic options for complex medical conditions from cancer to Crohn’s disease.

TypePrivate
Founded2016
HQWarren, NJ, US
Websitecelularity.com
Employee Ratings2.6

Latest Updates

Employees (est.) (Jun 2021)183(+2%)
Cybersecurity ratingCMore

Key People/Management at Celularity

Robert J Hariri

Robert J Hariri

Chairman, Founder & CEO
Henri Ji

Henri Ji

Director
Robin Smith

Robin Smith

Director
Xiaokui Zhang

Xiaokui Zhang

Chief Scientific Officer
Peter H. Diamandis

Peter H. Diamandis

Director
Keary Dunn

Keary Dunn

General Counsel & Business Development Head
Show more

Celularity Office Locations

Celularity has offices in Warren and Madison
Warren, NJ, US (HQ)
33 Technology Dr S
Madison, NJ, US
170 Park Ave
Show all (2)

Celularity Financials and Metrics

Summary Metrics

Founding Date

2016

Celularity total Funding

$290 m

Celularity latest funding size

$250 m

Time since last funding

3 years ago

Celularity investors

Celularity's latest funding round in February 2018 was reported to be $250 m. In total, Celularity has raised $290 m
Show all financial metrics

Celularity Cybersecurity Score

Cybersecurity ratingPremium dataset

C

72/100

SecurityScorecard logo

Celularity Online and Social Media Presence

Embed Graph

Celularity News and Updates

Celularity Appoints Bradley Glover, Ph.D. as Executive Vice President and Chief Technology Officer

Pharmaceutical industry veteran brings more than 20 years of business and technical operations experience across various commercial and development products Pharmaceutical industry veteran brings more than 20 years of business and technical operations experience across various commercial and develop…

Celularity Enters into Multi-Year Strategic Partnership with Palantir Technologies

Celularity to leverage Palantir’s next generation software and computational capabilities with their deep cellular data set to accelerate research and development activities

GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination

NEW YORK, April 16, 2021 /PRNewswire/ -- On April 14, 2021, GX Acquisition Corp. ("GX") (NASDAQ: "GXGX"), provided information regarding a proposal to amend GX's amended and restated certificate of incorporation (the "Charter") to extend the date by which GX has to complete its initial...

Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatment of Malignant Gliomas

FLORHAM PARK, N.J., April 13, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, announced today the …

Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

Presentations to showcase updates related to multiple Celularity programs in immuno-oncology and infectious disease Presentations to showcase updates related to multiple Celularity programs in immuno-oncology and infectious disease

Celularity Announces Fast Track Designation by the FDA for its Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme

FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, announced that the c…
Show more

Celularity Blogs

Celularity Gains FDA Orphan Drug Status on Strength of Placental Stem Cell Trials

On Tuesday, Celularity received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its off-the-shelf natural killer cell therapy for malignant gliomas. The news coincided with the American Association for Cancer Research (AACR) Annual Meeting 2021, where Celularity delivere…

Celularity Announces Fast Track Designation by the FDA for our Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme

FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, announced that the comp…

Investor Conference Call Transcript

Thank you for joining the conference call to introduce the proposed merger agreement between GX Acquisition Corp. and Celularity Inc. I would like to introduce Dean Kehler, Co-Chief Executive Officer of GX Acquisition Corp., to start the call.   DEAN KEHLER:   Thank you, everyone, and good morning. …

Celularity Frequently Asked Questions

  • When was Celularity founded?

    Celularity was founded in 2016.

  • Who are Celularity key executives?

    Celularity's key executives are Robert J Hariri, Henri Ji and Robin Smith.

  • How many employees does Celularity have?

    Celularity has 183 employees.

  • Who are Celularity competitors?

    Competitors of Celularity include TCR CURE Biopharma, Dualogics and Quentis Therapeutics.

  • Where is Celularity headquarters?

    Celularity headquarters is located at 33 Technology Dr S, Warren.

  • Where are Celularity offices?

    Celularity has offices in Warren and Madison.

  • How many offices does Celularity have?

    Celularity has 2 offices.